Real-World Use of Cladribine Tablets (Completion Rates and Treatment Persistence) in Patients with Multiple Sclerosis in England: the CLARENCE Study
Cladribine tablets (CladT; 3.5 mg/kg cumulative dose over 2 years) have been available in England for the treatment of highly active relapsing multiple sclerosis (MS) since 2017. As a compulsory requirement of National Health Service (NHS) reimbursement, all disease-modifying therapies (DMTs) prescr...
Saved in:
Published in | Multiple sclerosis and related disorders Vol. 71; p. 104286 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier B.V
01.03.2023
|
Online Access | Get full text |
Cover
Loading…
Abstract | Cladribine tablets (CladT; 3.5 mg/kg cumulative dose over 2 years) have been available in England for the treatment of highly active relapsing multiple sclerosis (MS) since 2017. As a compulsory requirement of National Health Service (NHS) reimbursement, all disease-modifying therapies (DMTs) prescribed for MS within NHS England must be registered via the Blueteq® high-cost drug database. The objective of current analysis was to evaluate real-world use of CladT in England using data collected by the Blueteq®platform, as part of the CLARENCE study. Here, we describe baseline characteristics, treatment completion rates (full course of CladT received) and treatment persistence (no need for switching/discontinuation) in patients treated with CladT in the real-world setting.
NHS England collect data on CladT use via the Blueteq®platform and provided the associated anonymised patient-level data to the study sponsor on a quarterly basis. Longitudinal data were collated for patients prescribed CladT between November 2017 and September 2021. Treatment history and Expanded Disability Status Scale (EDSS) scores were recorded at CladT initiation. Change in EDSS score, treatment completion, and persistence were evaluated over the length of the study. Data were analysed descriptively.
In total, 1934 patients prescribed CladT had a completed Blueteq form®; at treatment initiation, median (minimum; maximum) EDSS score was 2.5 (0; 8.5) and 691 (36%) patients were treatment naïve. Over the 2-year treatment course, 505 (83%) patients had a stable EDSS score (defined as no change; or decrease). At data cut-off, 1020 (53%) patients had completed the full course of CladT, 742 (38%) had received the first course with <18 months of follow-up, and 172 (9%) discontinued treatment before completing the second course of CladT. Overall, 78 (4%) patients switched to another DMT; of those, 45 (58%) received one treatment course of CladT and 33 (42%) received two courses.
Patients treated with CladT in England showed high rates of treatment completion and persistence (low switching rate of 4%), with stable EDSS scores across the planned 2 years of treatment. These findings highlight the real-world effectiveness of CladT in patients with highly active relapsing MS. |
---|---|
AbstractList | Cladribine tablets (CladT; 3.5 mg/kg cumulative dose over 2 years) have been available in England for the treatment of highly active relapsing multiple sclerosis (MS) since 2017. As a compulsory requirement of National Health Service (NHS) reimbursement, all disease-modifying therapies (DMTs) prescribed for MS within NHS England must be registered via the Blueteq® high-cost drug database. The objective of current analysis was to evaluate real-world use of CladT in England using data collected by the Blueteq®platform, as part of the CLARENCE study. Here, we describe baseline characteristics, treatment completion rates (full course of CladT received) and treatment persistence (no need for switching/discontinuation) in patients treated with CladT in the real-world setting.
NHS England collect data on CladT use via the Blueteq®platform and provided the associated anonymised patient-level data to the study sponsor on a quarterly basis. Longitudinal data were collated for patients prescribed CladT between November 2017 and September 2021. Treatment history and Expanded Disability Status Scale (EDSS) scores were recorded at CladT initiation. Change in EDSS score, treatment completion, and persistence were evaluated over the length of the study. Data were analysed descriptively.
In total, 1934 patients prescribed CladT had a completed Blueteq form®; at treatment initiation, median (minimum; maximum) EDSS score was 2.5 (0; 8.5) and 691 (36%) patients were treatment naïve. Over the 2-year treatment course, 505 (83%) patients had a stable EDSS score (defined as no change; or decrease). At data cut-off, 1020 (53%) patients had completed the full course of CladT, 742 (38%) had received the first course with <18 months of follow-up, and 172 (9%) discontinued treatment before completing the second course of CladT. Overall, 78 (4%) patients switched to another DMT; of those, 45 (58%) received one treatment course of CladT and 33 (42%) received two courses.
Patients treated with CladT in England showed high rates of treatment completion and persistence (low switching rate of 4%), with stable EDSS scores across the planned 2 years of treatment. These findings highlight the real-world effectiveness of CladT in patients with highly active relapsing MS. |
ArticleNumber | 104286 |
Author | Brownlee, Wallace Herbert, Alex Amin, Amerah Ashton, Luke |
Author_xml | – sequence: 1 givenname: Wallace surname: Brownlee fullname: Brownlee, Wallace organization: Queen Square MS Centre, UCL Institute of Neurology, London, United Kingdom – sequence: 2 givenname: Amerah surname: Amin fullname: Amin, Amerah organization: Merck Serono Ltd., (An Affiliate of Merck Kgaa), Feltham, United Kingdom – sequence: 3 givenname: Luke surname: Ashton fullname: Ashton, Luke organization: Merck Serono Ltd., (An Affiliate of Merck Kgaa), Feltham, United Kingdom – sequence: 4 givenname: Alex surname: Herbert fullname: Herbert, Alex organization: Merck Serono Ltd., (An Affiliate of Merck Kgaa), Feltham, United Kingdom |
BookMark | eNp9UMFOGzEQtRCVoDRfwGWO9LDpjtfr3VTqAa3SUim0KAniaDn2LDjaeJFtWvEffDAOqXpkLjN6eu_pzfvIjv3oibFzLKdYovyyne6iDnbKS84zIngrj9gp54hFWdXy-P8t2hM2iXFb5pE1Comn7GVJeijuxjBYuI0EYw_doG1wG-cJ1nozUIpw0Y27x3y50cNSJ4qgvYV1IJ125BPcUIguJvKGPoPzcKOTy3iEvy49wPXTkFyWw8oMFMbM3HPm_n7ILl8hPRB0i8vl_Fc3h1V6ss-f2IdeD5Em__YZu_0-X3dXxeL3j5_d5aIwKFpZzMys7KUwBluDJNq6abmQM9Niozea27qpmkabRrdN3c8MSr2pao0oOFqBfVOdserga3KqGKhXj8HtdHhWWKp9t2qr3rpV-27Vodus-nZQUY72x1FQ0bj969YFMknZ0b2rfwW0eYUk |
CitedBy_id | crossref_primary_10_1016_j_msard_2024_105704 |
ContentType | Journal Article |
Copyright | 2022 |
Copyright_xml | – notice: 2022 |
DBID | AAYXX CITATION |
DOI | 10.1016/j.msard.2022.104286 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2211-0356 |
ExternalDocumentID | 10_1016_j_msard_2022_104286 S2211034822007908 |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1P~ 1~. 1~5 4.4 457 4G. 53G 5VS 7-5 8P~ AACTN AADPK AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAXLA AAXUO ABBQC ABCQJ ABGSF ABJNI ABLVK ABMAC ABMZM ABTEW ABUDA ABXDB ABYKQ ACDAQ ACGFS ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEHWI AEKER AENEX AEVXI AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGWIK AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BKOJK BLXMC BNPGV DOVZS EBS EFJIC EFLBG EJD FDB FEDTE FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM LCYCR M41 MO0 MOBAO O-L O9- OAUVE OP~ P-8 P-9 PC. Q38 RIG ROL SDF SEL SPCBC SSH SSN SSU SSZ T5K Z5R ~G- AAXKI AAYXX AFJKZ AKRWK CITATION |
ID | FETCH-LOGICAL-c1486-9c90f64cc18c1e485782469c817aba2d57377ac7a875f9c16ab35a11421d41f73 |
IEDL.DBID | AIKHN |
ISSN | 2211-0348 |
IngestDate | Thu Sep 26 17:01:09 EDT 2024 Fri Feb 23 02:35:46 EST 2024 |
IsPeerReviewed | false |
IsScholarly | true |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1486-9c90f64cc18c1e485782469c817aba2d57377ac7a875f9c16ab35a11421d41f73 |
ParticipantIDs | crossref_primary_10_1016_j_msard_2022_104286 elsevier_sciencedirect_doi_10_1016_j_msard_2022_104286 |
PublicationCentury | 2000 |
PublicationDate | March 2023 2023-03-00 |
PublicationDateYYYYMMDD | 2023-03-01 |
PublicationDate_xml | – month: 03 year: 2023 text: March 2023 |
PublicationDecade | 2020 |
PublicationTitle | Multiple sclerosis and related disorders |
PublicationYear | 2023 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
SSID | ssj0000651461 |
Score | 2.2996264 |
Snippet | Cladribine tablets (CladT; 3.5 mg/kg cumulative dose over 2 years) have been available in England for the treatment of highly active relapsing multiple... |
SourceID | crossref elsevier |
SourceType | Aggregation Database Publisher |
StartPage | 104286 |
Title | Real-World Use of Cladribine Tablets (Completion Rates and Treatment Persistence) in Patients with Multiple Sclerosis in England: the CLARENCE Study |
URI | https://dx.doi.org/10.1016/j.msard.2022.104286 |
Volume | 71 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEF5qC-JFfGJ9lDl4UDC2STbZxlsplvpokT7AW9huNhDRtDT14MVf4Q92JtmIgnjwGrIw2dnMa7_5hrFT9OHSC3hgaR5Ji7tKWEEbjaFAdy8DjPDjKEdbDP3-lN8-eo8V1i17YQhWaWx_YdNza22eNM1uNhdJ0hw7lLsQNwuV2wJq-K2hO-K8ymqdm7v-8KvUgl6WplfTmDmHCoK4puQfypFeLxkqA1NFx6Ebz7yt-jcf9c3v9LbYpgkYoVPItM0qOt1h6wNzJb7LPkYY6lk5JgammYZ5DN1nGS0TTHk1TKgzapXBGf33xLM9T2FE4SXINIJJiTIHAsKTwvHzzyFJ4aGgW82A6rQwMKhDGKMIKHKS0Ttm_scVYAwJ3fvOiKpVQMDEtz027V1Pun3LjFqwFOZDvhWooBX7XCm7rWzN20Ryj4mzQrXJmXQiT7hCSCUkpjdxoGxfzlxPUh-uHXE7Fu4-q6bzVB8woCFXLRXZM6eliflQenashHJ9N3Z0OxZ1dlFubrgoGDXCEmr2FOa6CEkXYaGLOvNLBYQ_DkaINv-vhYf_XXjENmimfAE0O2bV1fJVn2DksZo12Nrlu90w5-sTlVXV6w |
link.rule.ids | 315,786,790,4521,24144,27955,27956,45618,45712 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEF6KgnoRn1ifc_CgYGzz3MRbCZaqbZE2hd7CZrOBiKalqQcv_gp_sDN5iIJ48BqyMNnZzHwz-80MY-fow4XtWZ6mrFholim55rloDDm6e-Ehwk_igm0xdHoT635qTxvMr2thiFZZ2f7SphfWunrSqnazNU_T1tig2IV6s1C6zaOC31VCA8Trun7XvxIt6GNpdjUNmTMoHYgr6u5DBc_rJUdVYKBoGHTfWRRV_-ahvnmd7hbbrOAidEqJtllDZTtsbVBdiO-yjxECPa1gxMAkVzBLwH8W8SLFgFdBQHVRyxwu6K-nLtuzDEYELkFkMQQ1xxyIBk_qxo-_hDSDx7LZag6UpYVBxTmEMYqAIqc5vVNN_7gBRJDg9zsjylUB0RLf9tikexv4Pa0atKBJjIYczZNeO3EsKXVX6spyqcU9hs0SlSYiYcQ2NzkXkgsMbhJP6o6ITFtQFa4eW3rCzX22ks0ydcCARly1ZaxHRltR30Nh64nk0nTMxFBuwpvsqt7ccF720whrotlTWOgiJF2EpS6azKkVEP44FiFa_L8WHv534Rlb7wWDfti_Gz4csQ2aLl9Szo7ZynLxqk4Qgyyj0-KMfQJ209bA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real-World+Use+of+Cladribine+Tablets+%28Completion+Rates+and+Treatment+Persistence%29+in+Patients+with+Multiple+Sclerosis+in+England%3A+the+CLARENCE+Study&rft.jtitle=Multiple+sclerosis+and+related+disorders&rft.au=Brownlee%2C+Wallace&rft.au=Amin%2C+Amerah&rft.au=Ashton%2C+Luke&rft.au=Herbert%2C+Alex&rft.date=2023-03-01&rft.issn=2211-0348&rft.volume=71&rft.spage=104286&rft_id=info:doi/10.1016%2Fj.msard.2022.104286&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_msard_2022_104286 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2211-0348&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2211-0348&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2211-0348&client=summon |